TY - JOUR
T1 - Simulated adoption of 2019 community-acquired pneumonia guidelines across 114 veterans affairs medical centers
T2 - Estimated impact on culturing and antibiotic selection in hospitalized patients
AU - Christensen, Matthew A.
AU - Nevers, McKenna
AU - Ying, Jian
AU - Haroldsen, Candace
AU - Stevens, Vanessa
AU - Jones, Makoto M.
AU - Yarbrough, Peter M.
AU - Goetz, Matthew Bidwell
AU - Restrepo, Marcos I.
AU - Madaras-Kelly, Karl
AU - Samore, Matthew H.
AU - Jones, Barbara Ellen
N1 - Publisher Copyright:
© 2021 Published by Oxford University Press for the Infectious Diseases Society of America 2021.
PY - 2021/1/15
Y1 - 2021/1/15
N2 - Background: The 2019 American Thoracic Society/Infectious Diseases Society of America guidelines for community-acquired pneumonia (CAP) revised recommendations for culturing and empiric broad-spectrum antibiotics. We simulated guideline adoption in Veterans Affairs (VA) inpatients. Methods: For all VA acute hospitalizations for CAP from 2006-2016 nationwide, we compared observed with guideline-expected proportions of hospitalizations with initial blood and respiratory cultures obtained, empiric antibiotic therapy with activity against methicillin-resistant Staphylococcus aureus (anti-MRSA) or Pseudomonas aeruginosa (antipseudomonal), empiric "overcoverage"(receipt of anti-MRSA/antipseudomonal therapy without eventual detection of MRSA/P. aeruginosa on culture), and empiric "undercoverage"(lack of anti-MRSA/antipseudomonal therapy with eventual detection on culture). Results: Of 115 036 CAP hospitalizations over 11 years, 17 877 (16%) were admitted to an intensive care unit (ICU). Guideline adoption would slightly increase respiratory culture (30% to 36%) and decrease blood culture proportions (93% to 36%) in hospital wards and increase both respiratory (40% to 100%) and blood (95% to 100%) cultures in ICUs. Adoption would decrease empiric selection of anti-MRSA (ward: 27% to 1%; ICU: 61% to 8%) and antipseudomonal (ward: 25% to 1%; ICU: 54% to 9%) therapies. This would correspond to greatly decreased MRSA overcoverage (ward: 27% to 1%; ICU: 56% to 8%), slightly increased MRSA undercoverage (ward: 0.6% to 1.3%; ICU: 0.5% to 3.3%), with similar findings for P. aeruginosa. For all comparisons, P < .001. Conclusions: Adoption of the 2019 CAP guidelines in this population would substantially change culturing and empiric antibiotic selection practices, with a decrease in overcoverage and slight increase in undercoverage for MRSA and P. aeruginosa.
AB - Background: The 2019 American Thoracic Society/Infectious Diseases Society of America guidelines for community-acquired pneumonia (CAP) revised recommendations for culturing and empiric broad-spectrum antibiotics. We simulated guideline adoption in Veterans Affairs (VA) inpatients. Methods: For all VA acute hospitalizations for CAP from 2006-2016 nationwide, we compared observed with guideline-expected proportions of hospitalizations with initial blood and respiratory cultures obtained, empiric antibiotic therapy with activity against methicillin-resistant Staphylococcus aureus (anti-MRSA) or Pseudomonas aeruginosa (antipseudomonal), empiric "overcoverage"(receipt of anti-MRSA/antipseudomonal therapy without eventual detection of MRSA/P. aeruginosa on culture), and empiric "undercoverage"(lack of anti-MRSA/antipseudomonal therapy with eventual detection on culture). Results: Of 115 036 CAP hospitalizations over 11 years, 17 877 (16%) were admitted to an intensive care unit (ICU). Guideline adoption would slightly increase respiratory culture (30% to 36%) and decrease blood culture proportions (93% to 36%) in hospital wards and increase both respiratory (40% to 100%) and blood (95% to 100%) cultures in ICUs. Adoption would decrease empiric selection of anti-MRSA (ward: 27% to 1%; ICU: 61% to 8%) and antipseudomonal (ward: 25% to 1%; ICU: 54% to 9%) therapies. This would correspond to greatly decreased MRSA overcoverage (ward: 27% to 1%; ICU: 56% to 8%), slightly increased MRSA undercoverage (ward: 0.6% to 1.3%; ICU: 0.5% to 3.3%), with similar findings for P. aeruginosa. For all comparisons, P < .001. Conclusions: Adoption of the 2019 CAP guidelines in this population would substantially change culturing and empiric antibiotic selection practices, with a decrease in overcoverage and slight increase in undercoverage for MRSA and P. aeruginosa.
KW - Empiric therapy
KW - Guideline
KW - Pneumonia
UR - http://www.scopus.com/inward/record.url?scp=85100688239&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100688239&partnerID=8YFLogxK
U2 - 10.1093/cid/ciaa1604
DO - 10.1093/cid/ciaa1604
M3 - Article
C2 - 33512530
AN - SCOPUS:85100688239
SN - 1058-4838
VL - 72
SP - S59-S67
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
ER -